A recent meta-analysis of SGLT-2 inhibitors among diabetic non-kidney transplant patients with chronic kidney disease demonstrated a modest reduction in HbA1C, body weight, and albuminuria [57]. Here, SLC5A2 is linked to chronic kidney disease.